| Zhang, Jin li |
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. |
|
|
| Completed | 3 | 517 | RoW | Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery | Qilu Pharmaceutical Co., Ltd. | Breast Cancer | 08/22 | 10/23 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer |
|
|
| Active, not recruiting | 1 | 10 | US | TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response | Washington University School of Medicine, Tesaro, Inc. | Endometrial Cancer, Cancer of the Endometrium | 03/24 | 12/25 | | |
| Lu, Wei |
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. |
|
|
| Recruiting | 3 | 108 | Europe, Japan, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT05776121: Study of ZB001 in Chinese Patients With Thyroid Eye Disease |
|
|
| Active, not recruiting | 1 | 17 | RoW | ZB001 for injection | Zenas BioPharma (USA), LLC | Thyroid Eye Disease | 10/24 | 10/24 | | |
NCT06047431: A Study of QL1706H in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 150 | NA | QL1706H | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/25 | | |
| Wang, Changli |
RATIONALE-315, NCT04379635: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 453 | RoW | Tislelizumab, BGB-A317, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin | BeiGene | Non Small Cell Lung Cancer | 06/25 | 11/25 | | |
|
| Recruiting | 3 | 390 | RoW | Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, Experimental, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, Active Comparator | 3D Medicines (Sichuan) Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 09/27 | | |
NCT04965831: Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) |
|
|
| Not yet recruiting | 2 | 40 | NA | Furmonertinib, AST2818 | Tianjin Medical University Cancer Institute and Hospital, Allist Pharmaceuticals, Inc. | Lung Adenocarcinoma | 03/23 | 05/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05088967: Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer |
|
|
| Terminated | 1 | 6 | RoW | IBI110, sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Non-small Cell Lung Cancer (NSCLC) | 12/21 | 12/23 | | |
| Guo, Zhi |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
| Ba, Yi |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04555304: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy |
|
|
| Not yet recruiting | 2 | 81 | NA | KH903 + Paclitaxel, Placebo + Paclitaxel | Chengdu Kanghong Biotech Co., Ltd. | Gastric Cancer, Gastroesophageal Cancer | 01/22 | 01/22 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin | Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd. | Biliary Tract Carcinoma | 12/24 | 12/25 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC |
|
|
| Not yet recruiting | 1 | 60 | NA | SCT-I10A, SCT200, Chemotherapy | Sinocelltech Ltd. | Esophageal Squamous Cell Carcinoma, Colorectal Cancer | 08/22 | 12/22 | | |
NCT04190823: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 63 | RoW | RC98, RC98 for Injection | RemeGen Co., Ltd. | Solid Tumors | 12/23 | 12/23 | | |
| Recruiting | 1 | 96 | RoW | TQB3454 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/22 | 12/22 | | |
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) |
|
|
| Recruiting | 1 | 24 | RoW | RC48-ADC, RC48-ADC injection, RC98, RC98 injection | RemeGen Co., Ltd. | Gastric Cancer | 05/24 | 09/24 | | |
| Not yet recruiting | 1 | 96 | RoW | KM501 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/26 | 12/27 | | |
| Zhang, Ti |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT03982303: Phase I Study of Hemay102 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 39 | RoW | Hemay102 | Tianjin Hemay Oncology Pharmaceutical Co., Ltd | Patients With Advanced Stage Solid Tumors | 12/21 | 12/21 | | |
| Liang, Han |
AK104-219, NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil | Akeso | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 11/24 | 11/27 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Hao, Jihui |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
BESTPOP, NCT05594927: Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, ) |
|
|
| Recruiting | 3 | 261 | RoW | Icaritin, Huachansu | Beijing Shenogen Biomedical Co., Ltd | Hepatocellular Carcinoma | 08/25 | 08/25 | | |
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. |
|
|
| Recruiting | 3 | 220 | RoW | Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide. | Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 12/26 | 10/30 | | |
2023-012-00CH1, NCT06361888: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 482 | RoW | Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine | Hutchmed | Metastatic Pancreatic Cancer | 08/27 | 08/27 | | |
NCT05208177: A Study of SHR-1802 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 2 | 124 | RoW | SHR-1802＋camrelizumab + famitinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05559541: Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 102 | RoW | AK119, AK104 | Akeso | Solid Tumor, Adult | 03/24 | 09/24 | | |
| Active, not recruiting | 1/2 | 220 | RoW | SHR-A1921； | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 02/26 | | |
NCT05868876: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 205 | RoW | AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion | Akeso | Advanced Malignant Tumors | 11/25 | 02/26 | | |
NCT04482257: Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. |
|
|
| Recruiting | 1 | 48 | RoW | Irinotecan Liposome Injection combined with 5-FU/LV | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Pancreatic Cancer | 12/20 | 03/21 | | |
NCT05173792: Study of AK119 in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 16 | RoW | AK119 | Akeso | Solid Tumor | 05/23 | 05/23 | | |
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1 | 67 | NA | HBM4003 and Triprilimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 05/24 | 05/24 | | |
NCT05125523: A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 264 | RoW | Sirolimus for Injection (Albumin Bound) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 06/24 | 11/24 | | |
| Recruiting | 1 | 65 | RoW | TQB3824 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 08/24 | 12/24 | | |
NCT05740202: A Trial of SHR-7367 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 182 | RoW | SHR-7367 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 11/25 | 11/25 | | |
| Wang, Ke |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
NCT06155396: A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Disitamab Vedotin, Disitamab Vedotin （RC48-ADC), Zimberelimab | RemeGen Co., Ltd. | Cervical Cancer | 06/27 | 12/27 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
TQB2450-II-14, NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. |
|
|
| Recruiting | 2 | 79 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Sarcoma of Uterus | 06/24 | 12/24 | | |
| Not yet recruiting | 2 | 20 | RoW | AK104 | Akeso | Vulvar Cancer | 08/24 | 02/25 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
NCT06798207: A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced |
|
|
| Not yet recruiting | 2 | 90 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gynecological Tumors | 05/26 | 11/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer |
|
|
| Recruiting | 1/2 | 54 | RoW | Bevacizumab； HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Recurrent Ovarian Cancer | 10/25 | 10/25 | | |
NCT05551507: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer |
|
|
| Recruiting | 1/2 | 150 | RoW | IN10018 in combination with PLD, IN10018 add on to PLD treatment | InxMed (Shanghai) Co., Ltd. | Platinum-resistant Ovarian Cancer | 06/24 | 12/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy |
|
|
| Recruiting | 1 | 40 | RoW | TQB2858 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cervical Cancer | 05/23 | 07/23 | | |
| Zhang, Huilai |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
NCT06149169: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma |
|
|
| Active, not recruiting | 2 | 10 | RoW | CD19-targeted Chimeric Antigen Receptor(CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | 10/24 | 03/25 | | |
NCT05590221: Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Peking University Cancer Hospital & Institute, Shanghai Ming Ju Biotechnology Co., Ltd. | B-cell Lymphoma | 02/24 | 12/24 | | |
| Recruiting | 2 | 12 | RoW | Relma-cel, CD19-targeted Chimeric Antigen Receptor(CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 04/25 | 12/26 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT06395870: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 33 | RoW | LUCAR-G39D cells product | Tianjin Medical University Cancer Institute and Hospital, Nanjing Legend Biotech Co. | B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | 06/26 | 06/28 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 10/25 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Completed | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda, Takeda Biopharmaceuticals India Pvt. Ltd. | Hunter Syndrome | 04/24 | 04/24 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India |
|
|
| Active, not recruiting | 4 | 5 | RoW | Replagal | Shire | Fabry Disease | 10/26 | 11/26 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
|
|
| Recruiting | 4 | 5 | US | ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG) | Takeda, Takeda Development Center Americas, Inc. | Mucopolysaccharidosis (MPS), Hunter Syndrome | 07/28 | 07/28 | | |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor |
|
|
| Completed | 3 | 73 | Europe, Canada, Japan, US | Lanadelumab, DX-2930, SHP643, TAK-743 | Shire, Takeda Development Center Americas, Inc. | Angioedema | 05/23 | 05/23 | | |
| Completed | 3 | 51 | Europe, Japan, US | BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 12/23 | 05/24 | | |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Active, not recruiting | 3 | 38 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
| Completed | 3 | 270 | Europe, Canada, Japan, US, RoW | Placebo, Soticlestat, TAK-935 | Takeda | Lennox Gastaut Syndrome (LGS) | 01/24 | 01/24 | | |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 34 | Europe, US, RoW | von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease | 01/25 | 01/25 | | |
